Eplerenone for the Treatment of Central Serous Chorioretinopathy

Eplerenone for the Treatment of Central Serous Chorioretinopathy

To test the effect oral eplerenone versus placebo in patients with central serious chorioretinopathy .

To evaluate the effect of oral eplerenone compared to placebo in patients with central serous chorioretinopathy (CSCR) on sub-foveal (small part of retina) fluid using optical coherence tomography (OCT).

Inclusion Criteria:

• Age 18 and over

• Ability to give written informed consent

• Sub-retinal fluid under fovea seen on OCT

• Diagnosis of central serous chorioretinopathy (CSCR): classification is at the discretion of the investigator, but general guidelines are

  1. Acute- first episode or symptoms less than one month prior to presentation
  2. Chronic- previously documented sub-foveal fluid, any prior treatment, symptoms for over 3 months, or <50% reduction in fluid thickness on OCT after 3 months.

Exclusion Criteria:

• Age under 18
• Impaired decision-making ability
• At initial laboratory screening serum potassium >5.5 milliequivalent (mEq)/L
• At initial laboratory screening serum creatinine >2 mg/dL in men and >1.8 mg/dL in women or decreased renal function by creatinine clearance less than 50 mL/min
• Absence of sub-foveal fluid
• Any patient with prior treatment for CSCR within 3 months of enrollment
• Patients taking potassium supplements or potassium-sparing diuretics spironolactone, amiloride, and triamterene and/or potent CYP3A4 (cytochrome) inhibitors (amifostine, cyclosporine, fluconazole, itraconazole, ketoconazole, mifepristone, posaconazole, potassium salts, rituximab, tacrolimus, voriconazole nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir)
• Women who are pregnant or are actively trying to conceive
• Patients with type 1 or type 2 diabetes